These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 8606262

  • 21. Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
    Weintraub WS, Culler S, Boccuzzi SJ, Cook JR, Kosinski AS, Cohen DJ, Burnette J.
    J Am Coll Cardiol; 1999 Oct; 34(4):1061-6. PubMed ID: 10520791
    [Abstract] [Full Text] [Related]

  • 22. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
    Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J.
    Circulation; 1993 Oct; 88(4 Pt 1):1512-7. PubMed ID: 8403299
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T, McGavin JK, Goa KL.
    Am J Cardiovasc Drugs; 2003 Oct; 3(5):381-6. PubMed ID: 14728074
    [Abstract] [Full Text] [Related]

  • 25. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study.
    Talarico GP, Brancati M, Burzotta F, Porto I, Trani C, De Vita M, Todaro D, Giammarinaro M, Leone AM, Niccoli G, Andreotti F, Mazzari MA, Schiavoni G, Crea F.
    J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin.
    Cohen M, Théroux P, Borzak S, Frey MJ, White HD, Van Mieghem W, Senatore F, Lis J, Mukherjee R, Harris K, Bigonzi F, ACUTE II Investigators.
    Am Heart J; 2002 Sep; 144(3):470-7. PubMed ID: 12228784
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.
    Circulation; 1998 Jun 23; 97(24):2386-95. PubMed ID: 9641689
    [Abstract] [Full Text] [Related]

  • 30. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction.
    Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E.
    Circulation; 1998 Feb 03; 97(4):340-9. PubMed ID: 9468207
    [Abstract] [Full Text] [Related]

  • 31. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.
    Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D.
    Am J Cardiol; 1995 Dec 15; 76(17):1222-7. PubMed ID: 7503000
    [Abstract] [Full Text] [Related]

  • 32. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R, FABOLUS PRO Investigators.
    JACC Cardiovasc Interv; 2012 Mar 15; 5(3):268-77. PubMed ID: 22440491
    [Abstract] [Full Text] [Related]

  • 33. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M, Théroux P, Weber S, Laramée P, Huynh T, Borzak S, Diodati JG, Squire IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo MW, White HD.
    Int J Cardiol; 1999 Dec 01; 71(3):273-81. PubMed ID: 10636535
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.